Viktor Gruenwald, MD, PhD

Panelists discuss emerging research directions and novel therapeutic combinations poised to shape the next generation of renal cell carcinoma management.

Panelists explore histology-specific and molecularly guided approaches that are expanding treatment options across renal cell carcinoma subtypes.

Panelists discuss strategies for recognizing, preventing, and managing toxicities associated with frontline combination regimens in advanced renal cell carcinoma.

Panelists discuss evolving evidence supporting adjuvant therapy in renal cell carcinoma and how these findings inform clinical decision-making.

Panelists analyze landmark clinical trial data supporting current frontline RCC therapies, focusing on response rates, progression-free survival, and overall benefit across risk groups.

Panelists discuss the epidemiology, histologic diversity, and evolving biology of advanced renal cell carcinoma, setting the stage for modern treatment selection.

Panelists review current guideline-endorsed first-line treatment options for advanced renal cell carcinoma, emphasizing immunotherapy- and VEGF inhibitor–based combination regimens.

Viktor Gruenwald, MD, PhD, discusses key results from a post-hoc analysis of the phase 3 CLEAR trial in advanced renal cell carcinoma.